Key result
Use of GLP-1 receptor agonists was associated with a reduced risk of serious renal events compared with DPP-4 inhibitors (4.8 vs 6.3 events per 1,000 person-years; HR 0.76; 95% CI 0.68-0.85).
Why the study?
The study was conducted to assess the association between the use of GLP-1 receptor agonists and the risk of serious renal events in routine clinical practice.
Do GLP-1 receptor agonists reduce serious renal events compared to DPP-4 inhibitors in patients in routine clinical practice?
Population
38,731 new users of GLP-1 receptor agonists matched 1:1 to DPP-4 inhibitor users across Sweden, Denmark, and Norway
Comparison
GLP-1 receptor agonists vs DPP-4 inhibitors
Design
Nationwide registry-based cohort study with active-comparator new-user design
Follow-up
Mean (SD) 3.0 (1.7) years
Authors
Loading...
May support preferring GLP-1 agonists for renal protection in routine care; extends observational data but leaves confirmation to randomized trials.
Cohort (n=77,462)
Yes
Do GLP-1 receptor agonists reduce serious renal events compared to DPP-4 inhibitors in patients in routine clinical practice?
Effect estimate: HR 0.76 (95% CI 0.68-0.85)
Absolute Event Rate: 4.8% vs 6.3%
Real-world data from Scandinavian registries demonstrates that GLP-1 receptor agonists are associated with a 24% relative risk reduction in serious renal events compared to DPP-4 inhibitors.
Pasternak et al. (2020) reported a cohort. GLP-1 receptor agonists vs. Dipeptidyl peptidase 4 (DPP-4) inhibitors was evaluated on Serious renal events (composite of renal replacement therapy, death from renal causes, and hospitalization for renal events) (HR 0.76, 95% CI 0.68-0.85). Use of GLP-1 receptor agonists was associated with a reduced risk of serious renal events compared with DPP-4 inhibitors (4.8 vs 6.3 events per 1,000 person-years; HR 0.76; 95% CI 0.68-0.85).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: